Recursion Pharmaceuticals Appoints New Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
Recursion Pharmaceuticals Inc. shares fell by 6.67% as the stock crossed below its 5-day SMA, reflecting investor caution following the announcement of a new Chief Medical Officer.
The company appointed Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro. Goodman brings over 20 years of oncology drug development experience, having previously served as CMO at Mural Oncology. Following this executive change, Recursion's shares dropped by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction. Despite this transition, Recursion aims to extend its cash runway into early 2028 while enhancing operational efficiency.
The appointment of Goodman may affect short-term market confidence, but the long-term strategy remains focused on innovative drug development. Investors will be watching closely to see how her extensive experience in oncology will influence Recursion's future projects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.960
Low
5.00
Averages
7.75
High
11.00
Current: 3.960
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Actively Buys Tesla and Other Stocks
- Tesla Delivery Growth: Despite a 7.5% drop in Tesla's stock price ahead of the Independence Day holiday, the company achieved a delivery of 480,126 vehicles in Q2, marking a 25% increase year-over-year, indicating strong market demand and production capability despite inventory challenges.
- SoFi Continuous Accumulation: Ark Invest increased its stake in SoFi Technologies every trading day this week, with membership reaching 14.7 million, a 35% year-over-year growth, and an adjusted EBITDA margin of 31%, showcasing its robust growth potential in the fintech sector.
- Recursion Drug Development: Ark's investment in Recursion Pharmaceuticals amounts to approximately $115 million, despite the company generating only $66 million in annual revenue and widening losses, its strategy of using AI to reinvent drug discovery has attracted significant investor interest.
- Market Reaction Analysis: While Tesla and SoFi's stock prices fluctuate, Cathie Wood's investment strategy reflects confidence in long-term growth, particularly in the current economic environment where investor interest in high-growth companies remains strong.
See More
Cathie Wood Increases Holdings in Three Stocks
- Tesla Investment Update: Cathie Wood holds approximately $1 billion in Tesla across all ETFs, and despite a 7.5% drop in stock price ahead of the Independence Day holiday, the company reported a strong second-quarter delivery of 480,126 vehicles, a 25% year-over-year increase, indicating robust market demand, particularly in Europe.
- SoFi Continuous Accumulation: Wood has been increasing her stake in SoFi Technologies daily this week, with current membership reaching 14.7 million, a 35% increase year-over-year, and an adjusted revenue growth rate of 41% alongside a 31% EBITDA margin, showcasing strong growth potential in the fintech sector.
- Recursion Pharmaceuticals Investment: Wood's investment in Recursion Pharmaceuticals amounts to approximately $115 million, representing over 5% of its outstanding shares, and although the company has trailing revenue of only $66 million and widening losses, its use of AI to reinvent drug discovery has attracted notable investors.
- Market Reaction Analysis: While Tesla's delivery figures exceeded analyst expectations, the market remains cautious about its future earnings due to the impact of promotional activities, yet Wood maintains an optimistic outlook on Tesla's long-term prospects, believing it will continue to dominate the electric vehicle market.
See More
Dyne vs Recursion: Biotechnology Investment Choices
- Dyne's Market Potential: Dyne Therapeutics focuses on therapies for muscle and central nervous system conditions, reporting a net loss of $446.2 million in FY 2025, yet its $3.7 billion market cap reflects investor confidence, with projected sales of $53 million in 2027 and over $1 billion by 2030.
- Recursion's AI Platform: Recursion Pharmaceuticals achieved approximately $74.7 million in revenue in FY 2025, a 27% increase, but faced a net loss of nearly $645 million, highlighting the high costs and risks associated with drug development.
- Funding Dependency Risks: Dyne relies solely on a loan from Hercules Capital for external funding, facing liquidity risks and needing to meet clinical and regulatory milestones for further funding, while Recursion depends on strategic partnerships with large pharmaceutical companies for capital, facing integration risks.
- Market Competition Outlook: While both companies are in development stages, Dyne is seen as closer to market with its upcoming DMD treatment, whereas Recursion may take years to achieve significant revenue, prompting investors to carefully assess their long-term growth potential.
See More
Investment Comparison: Dyne vs Recursion
- Dyne's Market Potential: Dyne Therapeutics focuses on therapies for muscle and central nervous system conditions, and despite having no revenue in FY 2025, its $3.7 billion market cap reflects investor confidence in its DMD treatment, with projected sales of $53 million in 2027 and over $1 billion by 2030.
- Recursion's AI Platform: Recursion Pharmaceuticals collaborates with major pharmaceutical companies like Roche and Takeda through its AI-driven drug discovery platform, achieving approximately $74.7 million in revenue for FY 2025, a 27% increase, yet still facing a net loss of nearly $645 million, highlighting the pressure of high R&D costs.
- Risk and Dependency: Dyne faces liquidity risks and relies on clinical and regulatory milestones to access loans, while Recursion is entirely dependent on the success of its AI platform, with any failures potentially leading to shareholder dilution and poor financial results.
- Valuation Comparison: Although Dyne is not expected to generate revenue in 2026, its market capitalization indicates investor confidence, whereas Recursion's valuation carries a significant premium relative to its current revenue, reflecting differing market perceptions of future potential.
See More
Investors Weigh Moderna Against Recursion in Biotech Landscape
- Moderna Financial Performance: In FY 2025, Moderna reported revenue exceeding $1.9 billion, a 40% decline from the previous year, resulting in a net loss of approximately $2.8 billion, reflecting financial pressure amid decreasing vaccine demand.
- Recursion Growth Potential: Recursion Pharmaceuticals generated approximately $74.7 million in revenue for FY 2025, marking a 27% year-over-year increase, despite a net loss of nearly $645 million, highlighting the tension between high investment in AI drug discovery and potential returns.
- Competitive Pressure Analysis: Moderna faces intense competition from large pharmaceutical companies like Pfizer and Sanofi, with regulatory policy changes potentially significantly impacting demand, while industry-wide uncertainty regarding mRNA intellectual property adds to future risks.
- Valuation Comparison: Moderna offers a lower sales multiple and a more established revenue base, whereas Recursion represents a higher-growth, earlier-stage investment with a price-to-sales ratio of 26.8, indicating market expectations for its future potential.
See More
Future Prospects of Moderna and Recursion
- Revenue and Loss Comparison: Moderna reported over $1.9 billion in revenue for FY 2025, a 40% decline year-over-year, resulting in a net loss of approximately $2.8 billion, indicating the financial pressures faced during its transformation.
- R&D Investment and Partnerships: By collaborating with companies like Merck, Moderna is expanding its pipeline into immuno-oncology and rare diseases, yet it must rely on these partnerships to drive research and commercialization amid fierce competition from giants like Pfizer.
- Recursion's Growth Potential: Recursion generated approximately $74.7 million in revenue for FY 2025, a 27% increase, but recorded a net loss of nearly $645 million, highlighting the high investment and risk profile in AI drug discovery, with future operations dependent on partnerships with firms like Roche.
- Market Outlook and Risks: While Moderna's mRNA platform has proven effective, declining demand for COVID vaccines has impacted its revenue, and Recursion faces uncertainties with its AI platform and potential cybersecurity risks, necessitating careful evaluation of both companies' long-term investment value.
See More
Cathie Wood Actively Buys Tesla and Other Stocks
- Tesla Delivery Growth: Despite a 7.5% drop in Tesla's stock price ahead of the Independence Day holiday, the company achieved a delivery of 480,126 vehicles in Q2, marking a 25% increase year-over-year, indicating strong market demand and production capability despite inventory challenges.
- SoFi Continuous Accumulation: Ark Invest increased its stake in SoFi Technologies every trading day this week, with membership reaching 14.7 million, a 35% year-over-year growth, and an adjusted EBITDA margin of 31%, showcasing its robust growth potential in the fintech sector.
- Recursion Drug Development: Ark's investment in Recursion Pharmaceuticals amounts to approximately $115 million, despite the company generating only $66 million in annual revenue and widening losses, its strategy of using AI to reinvent drug discovery has attracted significant investor interest.
- Market Reaction Analysis: While Tesla and SoFi's stock prices fluctuate, Cathie Wood's investment strategy reflects confidence in long-term growth, particularly in the current economic environment where investor interest in high-growth companies remains strong.
See More
Cathie Wood Increases Holdings in Three Stocks
- Tesla Investment Update: Cathie Wood holds approximately $1 billion in Tesla across all ETFs, and despite a 7.5% drop in stock price ahead of the Independence Day holiday, the company reported a strong second-quarter delivery of 480,126 vehicles, a 25% year-over-year increase, indicating robust market demand, particularly in Europe.
- SoFi Continuous Accumulation: Wood has been increasing her stake in SoFi Technologies daily this week, with current membership reaching 14.7 million, a 35% increase year-over-year, and an adjusted revenue growth rate of 41% alongside a 31% EBITDA margin, showcasing strong growth potential in the fintech sector.
- Recursion Pharmaceuticals Investment: Wood's investment in Recursion Pharmaceuticals amounts to approximately $115 million, representing over 5% of its outstanding shares, and although the company has trailing revenue of only $66 million and widening losses, its use of AI to reinvent drug discovery has attracted notable investors.
- Market Reaction Analysis: While Tesla's delivery figures exceeded analyst expectations, the market remains cautious about its future earnings due to the impact of promotional activities, yet Wood maintains an optimistic outlook on Tesla's long-term prospects, believing it will continue to dominate the electric vehicle market.
See More
Dyne vs Recursion: Biotechnology Investment Choices
- Dyne's Market Potential: Dyne Therapeutics focuses on therapies for muscle and central nervous system conditions, reporting a net loss of $446.2 million in FY 2025, yet its $3.7 billion market cap reflects investor confidence, with projected sales of $53 million in 2027 and over $1 billion by 2030.
- Recursion's AI Platform: Recursion Pharmaceuticals achieved approximately $74.7 million in revenue in FY 2025, a 27% increase, but faced a net loss of nearly $645 million, highlighting the high costs and risks associated with drug development.
- Funding Dependency Risks: Dyne relies solely on a loan from Hercules Capital for external funding, facing liquidity risks and needing to meet clinical and regulatory milestones for further funding, while Recursion depends on strategic partnerships with large pharmaceutical companies for capital, facing integration risks.
- Market Competition Outlook: While both companies are in development stages, Dyne is seen as closer to market with its upcoming DMD treatment, whereas Recursion may take years to achieve significant revenue, prompting investors to carefully assess their long-term growth potential.
See More
Investment Comparison: Dyne vs Recursion
- Dyne's Market Potential: Dyne Therapeutics focuses on therapies for muscle and central nervous system conditions, and despite having no revenue in FY 2025, its $3.7 billion market cap reflects investor confidence in its DMD treatment, with projected sales of $53 million in 2027 and over $1 billion by 2030.
- Recursion's AI Platform: Recursion Pharmaceuticals collaborates with major pharmaceutical companies like Roche and Takeda through its AI-driven drug discovery platform, achieving approximately $74.7 million in revenue for FY 2025, a 27% increase, yet still facing a net loss of nearly $645 million, highlighting the pressure of high R&D costs.
- Risk and Dependency: Dyne faces liquidity risks and relies on clinical and regulatory milestones to access loans, while Recursion is entirely dependent on the success of its AI platform, with any failures potentially leading to shareholder dilution and poor financial results.
- Valuation Comparison: Although Dyne is not expected to generate revenue in 2026, its market capitalization indicates investor confidence, whereas Recursion's valuation carries a significant premium relative to its current revenue, reflecting differing market perceptions of future potential.
See More
Investors Weigh Moderna Against Recursion in Biotech Landscape
- Moderna Financial Performance: In FY 2025, Moderna reported revenue exceeding $1.9 billion, a 40% decline from the previous year, resulting in a net loss of approximately $2.8 billion, reflecting financial pressure amid decreasing vaccine demand.
- Recursion Growth Potential: Recursion Pharmaceuticals generated approximately $74.7 million in revenue for FY 2025, marking a 27% year-over-year increase, despite a net loss of nearly $645 million, highlighting the tension between high investment in AI drug discovery and potential returns.
- Competitive Pressure Analysis: Moderna faces intense competition from large pharmaceutical companies like Pfizer and Sanofi, with regulatory policy changes potentially significantly impacting demand, while industry-wide uncertainty regarding mRNA intellectual property adds to future risks.
- Valuation Comparison: Moderna offers a lower sales multiple and a more established revenue base, whereas Recursion represents a higher-growth, earlier-stage investment with a price-to-sales ratio of 26.8, indicating market expectations for its future potential.
See More
Future Prospects of Moderna and Recursion
- Revenue and Loss Comparison: Moderna reported over $1.9 billion in revenue for FY 2025, a 40% decline year-over-year, resulting in a net loss of approximately $2.8 billion, indicating the financial pressures faced during its transformation.
- R&D Investment and Partnerships: By collaborating with companies like Merck, Moderna is expanding its pipeline into immuno-oncology and rare diseases, yet it must rely on these partnerships to drive research and commercialization amid fierce competition from giants like Pfizer.
- Recursion's Growth Potential: Recursion generated approximately $74.7 million in revenue for FY 2025, a 27% increase, but recorded a net loss of nearly $645 million, highlighting the high investment and risk profile in AI drug discovery, with future operations dependent on partnerships with firms like Roche.
- Market Outlook and Risks: While Moderna's mRNA platform has proven effective, declining demand for COVID vaccines has impacted its revenue, and Recursion faces uncertainties with its AI platform and potential cybersecurity risks, necessitating careful evaluation of both companies' long-term investment value.
See More
